Zacks Investment Research lowered shares of Replimune Group (NASDAQ:REPL) from a hold rating to a sell rating in a research note issued to investors on Tuesday.

According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

Shares of NASDAQ:REPL opened at $10.97 on Tuesday. Replimune Group has a twelve month low of $8.88 and a twelve month high of $23.55.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Wednesday, November 14th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). On average, equities analysts predict that Replimune Group will post -1.21 earnings per share for the current year.

Large investors have recently modified their holdings of the company. TIAA CREF Investment Management LLC acquired a new position in shares of Replimune Group during the third quarter worth approximately $164,000. Bank of New York Mellon Corp acquired a new position in shares of Replimune Group during the third quarter worth approximately $319,000. Zimmer Partners LP acquired a new position in shares of Replimune Group during the third quarter worth approximately $322,000. Laurion Capital Management LP acquired a new position in shares of Replimune Group during the third quarter worth approximately $322,000. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Replimune Group during the third quarter worth approximately $637,000. 55.75% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

See Also: Should you buy a closed-end mutual fund?

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.